AGNG

Aging Population ETF

Morningstar Rating™ - Overall rating out of 160 Health funds, based on risk-adjusted returns as of 08/31/2026

Key Information

As of Oct 12 2026
Inception Date
05/09/16
Total Expense Ratio
0.50%
Net Assets
$88.53 million
NAV
$36.43
Fact Sheet

ETF Summary

The Global X Aging Population ETF (AGNG) seeks to invest in companies positioned to serve the world’s growing senior population through exposure to health care, pharmaceuticals, senior living facilities and other sectors that contribute to increasing lifespans and extending quality of life in advanced age.

ETF Objective

The Global X Aging Population ETF (AGNG) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Indxx Aging Population Thematic Index.

Trading Details

As of Oct 12 2026
Ticker
AGNG
Bloomberg Index Ticker
ILNGRNT
CUSIP
37954Y772
ISIN
US37954Y7720
Primary Exchange
Nasdaq
Shares Outstanding
2,430,000
Number of Holdings
83
30-Day Median Bid-Ask Spread
0.36%
Distributions

ETF Prices

As of Oct 12 2026
NAV$36.43Daily Change$0.280.77%
Market Price$36.42Daily Change$0.200.55%

Performance History

As of recent month & quarter-end (Sep 30 2026)

Fund NAVMarket PriceIndex
1 Year10.58%10.37%11.05%
3 Years12.88%13.04%13.33%
5 Years5.50%5.67%5.85%
10 Years9.22%9.19%9.54%
Since Inception9.65%9.87%9.97%

Performance is shown on a total return basis (i.e., with gross income reinvested, where applicable). Cumulative return is the aggregate amount that an investment has gained or lost over time. Annualized return is the average return gained or lost by an investment each year over a given time period.

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. High short-term performance, when observed, is unusual and investors should not expect such performance to be repeated.

Top Holdings

As of Oct 12 2026
Net Assets (%)TickerNameSEDOLMarket Price ($)Shares HeldMarket Value ($)
3.95ABBVABBVIE INCB92SR70281.1212,4293,494,040.48
3.69LLYELI LILLY & CO25161521,182.622,7643,268,761.68
3.54MRKMERCK & CO. INC.2778844145.4521,5193,129,938.55
3.50AMGNAMGEN INC2023607417.577,4243,100,039.68
3.33WELLWELLTOWER INCBYVYHH4230.2912,7942,946,330.26
3.26JNJJOHNSON & JOHNSON2475833263.7310,9402,885,206.20
3.26EWEDWARDS LIFESCIENCES CORP256711686.3933,3542,881,452.06
3.19RO SWROCHE HOLDING AG-BR7108918443.256,3712,823,919.21
3.12MDTMEDTRONIC PLCBTN1Y1191.9330,0312,760,749.83
3.07NOVOB DCNOVO NORDISK A/S-BBP6KMJ138.3270,9122,717,641.48

Holdings are subject to change. "Cash" denotes U.S. dollars.

Exposure

As of Sep 30 2026
SectorWeight (%)
Health Care91.4
Real Estate8.6

Source: AltaVista Research, LLC

All Sector, Industry and Geographic breakdowns, where provided, are based on equity positions held by the ETF and exclude cash, currencies, and other holdings.

ETF Characteristics

As of Oct 12 2026
Return on Equity15.20%
Weighted Avg. Market Cap144,174 M
20252026
Price-to-earnings22.2119.48
Price-to-book value3.132.81

ETF Risk Stats

As of Sep 30 2026
VERSUSBETA
S&P 5000.42
NASDAQ-1000.12
MSCI EAFE0.50
MSCI Emg. Mkts0.12
Standard Deviation12.60%

ETF Research

Investing in Pharma: How to Spot Leading Drug Candidates

Investing in Pharma: The Drug Lifecycle

In the Pipeline: Top Drug Candidates for FDA Approval in 2024

ETF Documents